INCHEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that a post-hoc analysis of the LIBERTY-CD study, which showed that the efficacy of ZYMFENTRA® (infliximab-dyyb) is ...
Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — A post hoc analysis of PULSAR trial data showed sustained fluid control at 2 years with fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback